SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate...
Hence then, the article about immunoforge to showcase proprietary platform technologies and next generation oncology phase 2 clinical pipelines at bio europe 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026 )
Also on site :
- Ageless Jane Seymour Takes Halloween Inspiration From 2 Iconic Roles—Dr. Quinn and ‘James Bond’s’ Solitaire
- Energy markets are adapting to the Iran war as a ‘forever conflict’ while oil producers keep supplies flowing and avoid ‘mutually assured destruction’
- Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges